Background: Opioids are commonly prescribed to manage pain associated with
| INTRODUCTION
The opioid epidemic related to prescription misuse has been a topic of recent intense scrutiny on a national level. 1 The number of opioid prescriptions in the U.S. has increased by 35% between the years 2002 and 2009. 2 Approximately 15.5 million adult Americans reported misusing prescription opioids, and 1.9 million met the diagnostic criteria for opioid prescription abuse. 2 Death resulting from overdosing on a prescribed opioid is far greater than the number of fatal overdoses caused by cocaine and heroin combined. [3] [4] [5] [6] It has been shown that chronic opioid use is associated with many adverse events including an increased risk of myocardial infarction, bowel obstruction, respiratory distress, falls, and fractures. [7] [8] [9] Inflammatory bowel disease (IBD) flares are characterized by symptoms of abdominal and pelvic pain and diarrhoea for which an opioid could be used for symptomatic relief. Rheumatologic extra-intestinal manifestations of IBD can be another aetiology of pain in this patient population. Pain associated with flares usually subsides following flare resolution; however, pain symptoms can persist in the absence of objective evidence of active disease. 10, 11 Worsening abdominal pain with continued or escalating doses of narcotics may manifest as narcotic bowel syndrome. 11 It has been reported that IBD is an independent risk factor for using higher dosages of opioids. 12 In fact, in England, there has been a 20% rise in opioid prescribing among IBD patients in the last 20 years. 1 Persistence of opioid use in previously opioid-naïve patients has been studied in patients prescribed opioids following various types of surgery. New persistent opioid use has been associated with different patient factors including behavioural and pain disorders. 13 In addition, appreciating the dangers of prescribing narcotics for patients with IBD is an important step in the prevention of narcotic misuse. 10 The aims of this study were (a) to determine the incidence of new persistent opioid use following IBD flares treated with oral corticosteroids; and (b) to identify patient factors associated with new persistent opioid use among opioid-naïve patients.
| ME TH ODS

| Design
We performed a retrospective cohort analysis to identify the incidence of and associations with persistent opioid use following IBD flares treated with oral corticosteroid.
| Data sources
We States. The databases use rigorous methods to ensure that claims and enrolment data are complete, accurate, and reliable. 13 The databases have been accurately used to evaluate health outcomes in various clinical settings. 13 Within these databases we examined outpatient visits, inpatient admissions, services, enrolment tables, and pharmacy claims.
Approval from the Institutional Review Board at the University of Michigan was obtained to evaluate the data (HUM00127665).
| Study sample
The International Classification of Diseases, Ninth Revision, Clinical
Modification diagnosis codes were used to identify patients 18 years or older with a diagnosis of IBD (555.x and 556.x). For the case definition of IBD we required at least three IBD codes on three different visit encounters, 14 or one IBD-related visit encounter associated with an IBD medication prescription (a 5-aminosalicylate, immunomodulator, or biologic), which were identified using National Drug Codes listed in pharmacy claims. 15 An IBD flare was defined by a new prescription for an oral systemic corticosteroid for at least 14 days not preceded by oral steroid use within the 120 days prior as is consistent with previously published literature. 16, 17 The reliability of this algorithm has been verified before with survey data. to categorize opioid users. 13 The algorithm we used to select the study cohort is summarized in (Figure 1) . A complete list of opioid medications, 5-aminosalicylates, immunomodulators, biologics, and corticosteroids can be found in Appendix 1. The median (IQR) Charlson comorbidity index in both cohorts was 0 (0-2). Patients with Crohn's disease, indeterminate colitis, and those on biologics were also more likely to become persistent opioid users. In contrast, patients on 5-aminosalicylate medications were less likely to become persistent opioid users (P < 0.05) ( Table 2) .
| Outcomes
In multivariable analysis, the independent predictors of new per- (Table 3) . These findings can be helpful in risk stratifying patients, weighing analgesic choices and alternatives, and providing counselling for opioid naïve patients when choosing an acute pain therapy for an IBD flare.
| DISCUSSION
Management strategies for chronic pain are a primary focus in the midst of the opioid epidemic. 18, [30] [31] [32] However, no clear consensus on guidelines regarding acute pain management surrounding an IBD flare have been investigated. A recent study showed that IBD patients are more likely to be prescribed narcotics in acute care settings such as emergency departments, urgent care settings, and surgical outpatient follow up visits. 33 Alternatives to opioids need to be considered in the management of pain related to IBD, including neuroleptic medications and psychotherapy. 34, 35 As such, further studies exploring the management of acute pain in IBD patients are warranted to address this need.
The limitations of this study are inherent to any large administrative databases; while these databases excel in evaluating global trends and patterns, they lack granularity. For instance, we were not able to determine the severity of IBD in each patient and stratify the patients accordingly. Likewise, other disease related issues such as anatomical location, perianal disease, age at onset, and tobacco use cannot be accurately measured in an administrative database. We are not able to further characterize opioid prescribers' specialty, institutional factors, such as differentiating urban and rural settings, or account for opioid diversion. Databases are subject to data entry errors which may lead to inaccurate billing codes. The Marketscan databases use rigorous methods to ensure that claims and enrolment data are complete, accurate, and reliable. 13 The databases have been accurately used to evaluate health outcomes in various clinical settings. 13 Persistent opioid use might have resulted from other factors such as IBD-related surgeries leading to extended opioid requirements. 
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